Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Liposomes
Reexamination Certificate
2006-05-09
2008-11-18
Kishore, Gollamudi (Department: 1612)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Liposomes
C264S004100, C264S004300
Reexamination Certificate
active
07452550
ABSTRACT:
This invention relates to liposomal antineoplastic agents (e.g., camptothecin) compositions and methods of using such compositions for treating neoplasia and for inhibiting angiogenesis. The compositions and methods are useful for modulating the plasma circulation half-life of an active agent.
REFERENCES:
patent: 4235871 (1980-11-01), Papahadjopoulos et al.
patent: 4501728 (1985-02-01), Geho et al.
patent: 4837028 (1989-06-01), Allen
patent: 5023087 (1991-06-01), Yau-Young
patent: 5543152 (1996-08-01), Webb et al.
patent: 5552156 (1996-09-01), Burke
patent: 5814335 (1998-09-01), Webb et al.
patent: 5837282 (1998-11-01), Fenske et al.
patent: 5976567 (1999-11-01), Wheeler et al.
patent: 6110491 (2000-08-01), Kirpotin
patent: 6355268 (2002-03-01), Slater et al.
patent: 6723338 (2004-04-01), Sarris et al.
patent: 7060828 (2006-06-01), Madden et al.
patent: WO 91/04019 (1991-04-01), None
patent: WO 95/08986 (1995-04-01), None
patent: WO 98/17256 (1998-04-01), None
patent: WO 99/13816 (1999-03-01), None
patent: WO 99/51202 (1999-10-01), None
patent: WO 00/23052 (2000-04-01), None
Allen, T., et al., “Subcutaneous Administration of Liposomes: A Comparison with the Intravenous and Intraperitoneal Routes of Injection,”Biochim Biophys Acta. 1150(1):9-16, Jul. 25, 1993.
Boman, N., et al., “Vincristine-induced Dermal Toxicity is Significantly Reduced When the Drug is Given in Liposomes,”Cancer Chemother Pharmacol., 37(4):351-5, 1996.
Burris, H., et al., “Activity of Topotecan, a New Topoisomerase I Inhibitor, Against Human Tumor Colony-Forming Units In Vitro,”J. Natl. Cancer Inst. 84(23):1816-1820, Dec. 2, 1992.
Clements, M., et al., “Antiangiogenic Potential of Camptothecin and Topotecan,”Cancer Chemother. Pharmacol. 44:pp. 411-416, 1999.
U.S. Appl. No. 60/215,556, filed Jun. 30, 2000, Madden et al.
U.S. Appl. No. 09/896,812, filed Jun. 29, 2001, Madden et al.
U.S. Appl. No. 60/264,616, filed Jan. 26, 2001, Madden et al.
Corbett, T., et al., chapter 5 “In Vivo Methods for Screening and Preclinical Testing,” in B. Teicher, Ed.,Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval, Humana Press Inc., Totowa, NJ, 1997, pp. 75-99.
Emerson, D., et al., “In Vivo Antitumor Activity of Two New Seven-substituted Water-soluble Camptothecin Analogues,”Cancer Res. 55:603-609, Feb. 1, 1995.
Erickson-Miller, C., et al., “Differential Toxicity of Camptothecin, Topotecan and 9-Aminocamptothecin to Human, Canine, and Murine Myeloid Progenitors (CFU-GM) in Vitro,”Cancer Chemother. Pharmacol. 39:467-472, 1997.
Grochow, L., et al., “Pharmacokinetics and Pharmacodynamics of Topotecan in Patients with Advanced Cancer,”Drug Metab. Dispos. 20(5):706-713, 1992.
Hardman, W., et al., “Efficacy of Treatment of Colon, Lung and Breast Human Carcinoma Xenografts With: Doxorubicin, Cisplatin, Irinotecan or Topotecan,”Anticancer Res. 19:2269-2274, 1999.
Hope, M., et al., “Generation of Multilamellar and Unilamellar Phospholipid Vesicles,”Chem. Phys. Lip. 40:89-107, 1986.
Madden, T., et al. “The Accumulation of Drugs Within Large Unilamellar Vesicles Exhibiting a Proton Gradient: A Survey,”Chem. Phys. Lipids 53:37-46, 1990.
Hsiang, Y-H., et al., “Identification of Mammalian DNA Topoisomerase I as an Intracellular Target of the Anticancer Drug Camptothecin,”Cancer Res. 48:1722-1726, Apr. 1988.
Kearney, A. et al., “Preformulation Studies to Aid in the Development of a Ready-to-Use Injectable Solution of the Antitumor Agent, Topotecan,”Int. J. Pharm. 127:229-237, 1996.
Gruner, S., chapter 1 “Materials Properties of Liposomal Bilayers,” in Ostro, M.J. (ed.),Liposomes: From Biophysics to Therapeutics, Marcel Dekker, New York, 1993, pp. 1-38.
Madden, T., et al., “Encapsulation of Topotecan in Lipid-based Carrier Systems. Evaluation of Drug Stability and Plasma Elimination in a Murine Model, and Comparison of Antitumor Efficacy Against Murine L1210 and B16 Tumors,”Proc. Of ASCO 17, abstract #754, 1998.
Mayer, L., et al., “Characterization of Liposomal Systems Containing Doxorubicin Entrapped in Response to pH Gradients,”Biochim. Biophys. Acta 1025:143-151, 1990.
McCabe, F., et al., “Comparative Activity of Oral and Parenteral Topotecan in Murine Tumor Models: Efficacy of Oral Topotecan,”Cancer Invest. 12(3):308-313, 1994.
O'Leary, J., et al., “Antiangiogenic Effects of Camptothecin Analogues 9-Amino-20 (S)-Camptothecin, Topotecan, and CPT-11 Studied in the Mouse Cornea Model,”Clin Cancer Res. 5:181-187, Jan. 1999.
Ormrod, D. et al., “Topotecan A Review of its Efficacy in Small Cell Lung Cancer,”Drugs 58(3):533-551, Sep. 1999.
Plowman, J., et al., chapter 6, “Human Tumor Xenograft Models in NCI Drug Development,” in B. Teicher, Ed,In Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval, Humana Press Inc., Totowa, NJ, 1997.
Szoka, F., et al., “Comparative Properties and Methods of Preparation of Lipid Vesicles (Liposomes),”Ann. Rev. Biophys. Bioeng. 9:467-508, 1980.
Tardi, P., et al., “Liposomal Encapsulation of Topotecan Enhances Anticancer Efficacy in Murine and Human Xenograft Models,”Cancer Res. 60:3389-3393, Jul. 2000.
Thompson, J., et al., “Animal Models for Studying the Action of Topoisomerase I Targeted Drugs,”Biochim. Biophys. Acta 1400:301-319, 1998.
Wall, M., et al., “Plant Antitumor Agents. I. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca Acuminata,”J. Am Chem. Soc. 88:3888-3890, Aug. 1966.
Waud, W., chapter 4 “Murine L1210 and P388 Leukemias,” In B. Teicher, Ed,Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval, Humana Press Inc., Totowa, NJ, 1997.
Ahkong Quet F.
Madden Thomas D.
Semple Sean C.
Hana Biosciences, Inc.
Kanik Cynthia L.
Kishore Gollamudi
Lahive & Cockfield LLP
Remillard Jane E.
LandOfFree
Liposomal antineoplastic drugs and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Liposomal antineoplastic drugs and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Liposomal antineoplastic drugs and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4051627